Delivra Health Teams Up With Canopy Growth To Manufacture And Distribute Its CBD Infused Topical Brand LivRelief

Delivra Health Brands Inc. DHBUF DHB announced that its wholly-owed subsidiary, Delivra Inc., has granted a subsidiary of Canopy Growth Corporation CGC, an exclusive strategic license agreement dated May, 23, 2023 to manufacture, distribute and sell infused LivRelief branded topicals in Canada.

"We are very pleased to announce our second agreement with Canopy, this time to secure more efficient and cost effective supply and distribution for our LivRelief infused branded topicals, such as the transdermal cream that ranked as the top selling transdermal cream in Canada as of January 2023," stated Gord Davey, president and CEO of Delivra Health. "We expect our collaboration with Canopy will realize benefits well beyond the availability of our product on Canopy's Spectrum Therapeutics' online medical store. Through the agreement, Canopy will be responsible for manufacturing, distributing and selling the of LivRelief products in Canada, and we strongly believe that as an industry leader, Canopy will be able to grow the LivRelief brand to its full potential."

LivRelief cannabis infused products are available nationally through Medical Cannabis by Shoppers as well as in cannabis stores throughout Ontario, British Columbia, Alberta, Saskatchewan, Manitoba, and New Brunswick.

LivRelief infused topicals are currently available in three SKUs - a CBD-only formulation containing 250mgs of CBD, a 1:1 format formulation containing 125mgs of THC and 125mgs of CBD, and an extra strength CBD topical cream containing 750mgs of CBD.

Photo: Benzinga edit with photos by jarmoluk and lindsayfox on Pixabay

Related News

Delivra Health Stock Soars On Q3 FY23 Positive Adjusted EBITDA, Here Are The Details

Delivra Health Stock Trading Higher On Reached Profitability

Delivra Health Brands Sells Its Lucky Lake Facility For $3M